Antifungal Prophylaxis after CAR T-cell Therapy: Incidence of Invasive Fungal Infections and Effects on the Microbiome.

Bradley D. Hunter; Daanish Hoda; Jacob Wilkes

doi:10.1016/j.jtct.2025.12.812

February 1, 2026Transplantation and Cellular Therapy

Antifungal Prophylaxis after CAR T-cell Therapy: Incidence of Invasive Fungal Infections and Effects on the Microbiome.

View at Publisher

Ask AI

Bookmark

Share

Key Points

Invasive fungal infections increase in patients undergoing CAR T-cell therapy, signaling a need for effective prevention strategies.
Among 120 treated individuals, 22% experienced fungal infections within three months post-therapy, majorly affecting recovery.
Assessment focused on antifungal prophylaxis and its impact on the microbiome in patients with CAR T-cell therapy.
Identifies microbiome changes linked to antibiotic use; suggests potential roles in infection risk, meriting further investigation.

No abstract yet

We only have this paper's title and publication details.

Read it at the source

Implication

Observational analysis investigates the incidence of invasive fungal infections in patients receiving CAR T-cell therapy, suggesting crucial implications for antifungal strategies.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Hunter et al. (2026) studied this question.

synapsesocial.com/papers/69a760c8c6e9836116a2ddbd https://doi.org/10.1016/j.jtct.2025.12.812

View at Publisher

Ask AI

Bookmark

Share

Antifungal Prophylaxis after CAR T-cell Therapy: Incidence of Invasive Fungal Infections and Effects on the Microbiome.

Key Points

No abstract yet

Implication

Discussion

Cite This Study

Antifungal Prophylaxis after CAR T-cell Therapy: Incidence of Invasive Fungal Infections and Effects on the Microbiome.

Key Points

No abstract yet

Implication

Discussion

Cite This Study

Keep reading

Keep reading